Garage Brain Science Co., Ltd.
Update：2026/03/31
Industries
Main Industry
Biotechnology
Main Product/Service
Preventive healthcare platform featuring AI Dr. Listening™, small-molecule protein structure repair drug Reprofold®, rapid misfolded protein screening FoldCheck™, and misfolded protein detection systems HIMP™ and eHIMP™.
Founded Year
2023
Unified Business No.
89172624
Status
Active
Number of Employees
8
Total Paid-in
Capital
17,536,700 (NT$)
Location of Company
Taiwan
, Taichung City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Garage Brain Science Co pioneered the “pre-symptomatic treatment platform,” combining AI-driven molecular diagnostics with protein structure repair therapies to prevent chronic diseases such as dementia and diabetes. Founded by scientists who discovered the link between protein misfolding and neurodegeneration, the company has developed proprietary technologies that integrate early detection, patient stratification, and preventive intervention. The diagnostic platform requires only 50 μL of blood and delivers misfolded protein detection in 3 hours with 92–98% accuracy, already aiding multinational pharmaceutical companies in expanding early-stage clinical trial populations. Its core drug, Reprofold®, can repair multiple misfolded proteins, with animal studies showing a 40% lifespan extension and potential across multiple disease treatments. Coupled with AI tools Dr. Listening™ and Disease Origin Finder™, GBS enables precise patient stratification and personalized prevention. The company is advancing U.S. clinical programs and collaborations, targeting the $300 billion preventive healthcare market.
